当前位置: X-MOL 学术Eur. J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of membrane-targeting amphiphilic honokiol derivatives containing an oxazolethione moiety to combat methicillin-resistant Staphylococcus aureus (MRSA) infections
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2024-09-10 , DOI: 10.1016/j.ejmech.2024.116868
Ruige Yang 1 , Liping Cui 2 , Ting Xu 3 , Yan Zhong 3 , Songlin Hu 3 , Jifeng Liu 2 , Shangshang Qin 2 , Xiaoliu Wang 4 , Yong Guo 1
Affiliation  

Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major pathogen causing infections in hospitals and the community, and there is an urgent need for the development of novel antibacterials to combat MRSA infections. Herein, a series of amphiphilic honokiol derivatives containing an oxazolethione moiety were prepared and evaluated for their in vitro antibacterial and hemolytic activities. The screened optimal derivative, I3, exhibited potent in vitro antibacterial activity against S. aureus and clinical MRSA isolates with MIC values of 2–4 μg/mL, which was superior to vancomycin in terms of its rapid bactericidal properties and was less susceptible to the development of resistance. The SARs analysis indicated that amphiphilic honokiol derivatives with fluorine substituents had better antibacterial activity than those with chlorine and bromine substituents. In vitro and in vivo toxicity studies revealed that I3 has relatively low toxicity. In a MRSA-infected mouse skin abscess model, I3 (5 mg/kg) effectively killed MRSA at the infected site and attenuated the inflammation effects, comparable to vancomycin. In a MRSA-infected mouse sepsis model, I3 (12 mg/kg) was found to significantly reduce the bacterial load in infected mice and increase survival of infected mice. Mechanistic studies indicated that I3 has membrane targeting properties and can interact with phosphatidylglycerol (PG) and cardiolipin (CL) of MRSA cell membranes, thereby disrupting MRSA cell membranes, further inducing the increase of reactive oxygen species (ROS), protein and DNA leakage to achieve rapid bactericidal effects. Finally, we hope that I3 is a potential candidate molecule for the development of antibiotics to conquer superbacteria-related infections.

中文翻译:


发现含有噁唑硫酮部分的靶向膜两亲性和厚朴酚衍生物,以对抗耐甲氧西林金黄色葡萄球菌 (MRSA) 感染



耐甲氧西林金黄色葡萄球菌 (MRSA) 已成为在医院和社区引起感染的主要病原体,迫切需要开发新型抗菌剂来对抗 MRSA 感染。在此,制备了一系列含有噁唑硫酮部分的两亲性和厚朴酚衍生物,并评价了它们的体外抗菌和溶血活性。筛选的最佳衍生物 I3 对金黄色葡萄球菌和临床 MRSA 分离株表现出有效的体外抗菌活性,MIC 值为 2-4 μg/mL,在其快速杀菌特性方面优于万古霉素,并且不易产生耐药性。SARs 分析表明,含氟取代基的两亲性和厚朴酚衍生物比含氯和溴取代基的两亲性和厚朴酚衍生物具有更好的抗菌活性。体外和体内毒性研究表明,I3 的毒性相对较低。在 MRSA 感染的小鼠皮肤脓肿模型中,I3 (5 mg/kg) 有效杀死感染部位的 MRSA 并减轻炎症作用,与万古霉素相当。在 MRSA 感染的小鼠败血症模型中,发现 I3 (12 mg/kg) 可显著降低感染小鼠的细菌载量并提高感染小鼠的存活率。机制研究表明,I3 具有膜靶向特性,可与 MRSA 细胞膜的磷脂酰甘油 (PG) 和心磷脂 (CL) 相互作用,从而破坏 MRSA 细胞膜,进一步诱导活性氧 (ROS) 的增加、蛋白质和 DNA 泄漏,从而达到快速杀菌效果。最后,我们希望 I3 是开发抗生素以征服超级细菌相关感染的潜在候选分子。
更新日期:2024-09-10
down
wechat
bug